clinical trial · NCT07071623
A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)
Merck Sharp & Dohme LLC·phase3·recruiting·n = 4,580
Human Immunodeficiency Virus (HIV)HIV Pre-Exposure ProphylaxisMK-8527Emtricitabine/tenofovir disoproxil (FTC/TDF)Placebo matched to MK-8527Placebo matched to FTC/TDF
brief summary
Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection. The goals of this study are to learn: * If taking MK-8527 once a month works to prevent HIV-1 infection better than a standard (usual) pre-exposure prophylaxis (PrEP) taken once a day * About the safety of MK-8527 and if people tolerate it
started
Nov 10, 2025
primary completion
Oct 18, 2027
completion
Oct 18, 2027
last updated
Jun 1, 2026
official title
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol